

Heller Ehrman White & McAuliffe LLP  
Attorney Docket No. 37794-0032

U.S. Serial No. 09/986,344  
Peter Law.

### Amendment to the Specification

Amend the paragraph on page 13, lines 27 to 41 by insertion of "--, now abandoned--" as shown below.

In accordance with one embodiment of the invention, fusion of the transduced myoblasts is facilitated by administration of large chondroitin-6-sulfate proteoglycan (LCSP) as described in the above-cited U.S. application Serial No. 08/477,377, now abandoned. Trauma from injecting myoblasts into the extracellular matrix triggers the release of basic fibroblast growth factor and large chondroitin-6-sulfate proteoglycan. These released molecules stimulate myoblast proliferation. Increasing the level of large chondroitin-6-sulfate proteoglycan at the injection site facilitates myoblast fusion and proliferation. According,, in accordance with one embodiment of the invention, large chondroitin-6-sulfate proteoglycan preferably is administered with the transduced myoblasts.